Warnex Inc.

Warnex Inc.

June 01, 2006 07:00 ET

Warnex Receives AOAC-RI Validation for Quantitative Campylobacter Test

LAVAL, QC, June 1 - Warnex Inc. (TSX:WNX) today announced that its
quantitative Campylobacter test used with the Warnex™ Rapid Pathogen
Detection System has been granted Performance Tested(SM) status by the AOAC
Research Institute (Certificate No. 050603) and is the first quantitative
real-time PCR test available to the food industry to be AOAC-validated.

"The validation of this test marks a major achievement for Warnex and
attests to the high potential of our real-time PCR platform and to our
scientific leadership in the development of state-of-the-art pathogen
detection tests for the food industry," said Mark Busgang, President and CEO.
"This validation will enhance the commercial appeal of the Warnex platform for
our prospective clients as well as broaden the applicability of our system for
existing customers."

The AOAC Research Institute is a non-profit international scientific
organization that administers the Performance Tested Methods(SM) Program.
Within this program, an independent third-party review showed that the Warnex
test detected and quantified Campylobacter in poultry rinses as well as, or
better than traditional culture methods. With no enrichment required, Warnex's
Campylobacter test provides results within as little as 3 hours.

According to the Centers for Disease Control and Prevention (CDC),
Campylobacter is one of the most common bacterial causes of diarrheal illness
in the United States, with an estimated 2.4 million cases every year. In
addition to diarrhea, Campylobacter infections cause cramping, abdominal pain,
and fever, and may occasionally cause a serious life-threatening infection for
persons with weakened immune systems. Warnex's Campylobacter test detects and
quantifies three species of this pathogen, Campylobacter jejuni, C. coli and
C. lari, which account for 99% of reported Campylobacter illness cases.

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in a
sample. The system allows for the simultaneous detection of multiple pathogens
and processing of samples within 3 to 48 hours, a significant improvement over
traditional microbiology tests that currently require 5 to 7 days.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
DNA-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing and meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and medical laboratory service groups
offer a variety of quality control services, method development and
validation, contract R&D, bioavailability and bioequivalence studies for
clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc., Laval, Quebec.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, manufacturing and laboratory facilities, suppliers,
key employees, key customers, financial resources and credit risk, government
regulations, foreign currency risk and volatility of share price, and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to the
heading Risks and Uncertainties in the Management's Discussion and Analysis
for the first quarter ended March 31, 2006, which can be found at
www.sedar.com. Consequently, actual results may differ materially from the
anticipated results expressed in these forward-looking statements.

Contact Information